Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This work characterizes the synthesis and SAR of a new chemical class and further validates PDI as a therapeutic target in MM as a single agent and in combination with proteasome inhibitors.
|
31787362 |
2020 |
Chronic pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
There was a trend toward improvement but no significant relationship between CBD use and PHQ and PDI.<b>Conclusion</b>: CBD could significantly reduce opioid use and improve chronic pain and sleep quality among patients who are currently using opioids for pain management.<b>Key Message</b>: This is a prospective, single-arm cohort study for the potential role of cannabinoids as an alternative for opioids.
|
31711352 |
2020 |
opioid use
|
0.010 |
Biomarker
|
disease |
BEFREE |
There was a trend toward improvement but no significant relationship between CBD use and PHQ and PDI.<b>Conclusion</b>: CBD could significantly reduce opioid use and improve chronic pain and sleep quality among patients who are currently using opioids for pain management.<b>Key Message</b>: This is a prospective, single-arm cohort study for the potential role of cannabinoids as an alternative for opioids.
|
31711352 |
2020 |
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Using FFQ data from adults (45-64 y, n = 8041) without hypertension at baseline in the Atherosclerosis Risk in Communities (ARIC) Study, we scored participants' diets using the overall PDI (oPDI), healthy PDI (hPDI), less healthy (unhealthy) PDI (uPDI), provegetarian diet index, and PDI from the Rotterdam Study (PDI-Rotterdam).
|
31722418 |
2019 |
Leishmaniasis, Visceral
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we selected Amastin, CaNA2, Kmp-11 and PDI proteins of Leishmania donovani for study, which are VL vaccine candidates or possible drug targets.
|
30582920 |
2019 |
Myopia
|
0.010 |
Biomarker
|
disease |
BEFREE |
To evaluate the ability of the PDI Check (PDI Check LLC, Anchorage, AK) near vision screening game to assess monocular acuity, stereopsis, suppression, and color.
|
31322713 |
2019 |
Osteogenesis Imperfecta
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
BMD = bone mineral density; MIM = Mendelian Inheritance in Man; OI = osteogenesis imperfecta; PDI = protein disulfide isomerase.
|
30913006 |
2019 |
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
PDI is associated with many diseases including neurodegenerative disorders like Alzheimer's disease and, hence, is considered a promising drug target.
|
31343165 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PDI expression (P<0.001) and the co-expression of PDI and ERO1A (P<0.001) were independent poor prognostic factors for OS in patients with NSCLC in multivariate analysis.
|
30344729 |
2018 |
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The ACA-PI was positively correlated with the PDI and MDI scores in fetuses with CHDs (r<sup>2</sup> = 0.26, 0.20, P < 0.01).
|
29540791 |
2018 |
Parasitic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
However, passive collection method had lower sensitivity than active collection method for the estimation of peridomestic infestation and intradomestic colonization (PDI: p< 0.01; ID colonization: p< 0.01).
|
30071071 |
2018 |
Anxiety
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The overall findings suggest that the workbook format was no less effective or acceptable than the validated online format.Significant improvements (avg. improvement; Internet Group vs Workbook Group) in levels of disability (PDI: 16% vs 24%; RMDQ: 12% vs 15%), anxiety (GAD-7: 36% vs 26%), and depression (PHQ-9: 36% vs 36%) were observed in both groups immediately posttreatment.
|
28394850 |
2017 |
Anxiety Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The overall findings suggest that the workbook format was no less effective or acceptable than the validated online format.Significant improvements (avg. improvement; Internet Group vs Workbook Group) in levels of disability (PDI: 16% vs 24%; RMDQ: 12% vs 15%), anxiety (GAD-7: 36% vs 26%), and depression (PHQ-9: 36% vs 36%) were observed in both groups immediately posttreatment.
|
28394850 |
2017 |
Bacterial Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The present study provides another type of anti-adhesive glycocluster against bacterial infection with a large aromatic PDI core.
|
29165489 |
2017 |
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neither prenatal exposure to BD- or BD+ significantly impacted overall PDI (P = .2449), MDI (P = .7886), or BRS (P = .6072) scores.
|
28068465 |
2017 |
Delusions
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Delusions Inventory (PDI-21) and to test the invariance of its factor structure over time and across samples.
|
28463717 |
2017 |
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Correlation analyses corrected for age, gender, pain intensity, pain duration and insulin treatment were performed to assess the associations of fear of hypoglycaemia (Hypoglycaemia Fear Survey, HFS), kinesiophobia (Tampa Scale of Kinesiophobia, TSK), fear of pain (Pain Anxiety Symptom Scale, PASS-20), fear of falling (Falls Efficacy Scale-I, FES-I), fear of fatigue (Tampa Scale of Fatigue, TSF) and fear of negative evaluation (Brief Fear of Negative Evaluation Scale, BFNE), with quality of life (QoL) (Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version, QOL-DN) and disability (Pain Disability Index, PDI), respectively.
|
28656745 |
2017 |
Hypoglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Correlation analyses corrected for age, gender, pain intensity, pain duration and insulin treatment were performed to assess the associations of fear of hypoglycaemia (Hypoglycaemia Fear Survey, HFS), kinesiophobia (Tampa Scale of Kinesiophobia, TSK), fear of pain (Pain Anxiety Symptom Scale, PASS-20), fear of falling (Falls Efficacy Scale-I, FES-I), fear of fatigue (Tampa Scale of Fatigue, TSF) and fear of negative evaluation (Brief Fear of Negative Evaluation Scale, BFNE), with quality of life (QoL) (Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version, QOL-DN) and disability (Pain Disability Index, PDI), respectively.
|
28656745 |
2017 |
Schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The PDI-21 was administered in two samples; one consisting of 1655 undergraduate students investigated in three waves, each separated by six months; and another consisting of 196 outpatients with schizophrenia.
|
28463717 |
2017 |
Peripheral Vascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
This study was a secondary analysis of the OMEGA-PAD I trial, a randomized, double-blinded, placebo-controlled trial investigating short-duration, high-dose n-3 PUFA oral supplementation on endothelial function and inflammation in subjects with peripheral arterial disease.
|
28457318 |
2017 |
Cerebral atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that the unfolded protein response (UPR) was strongly activated after HI injury and that bFGF significantly reduced the levels of the ER stress signalling proteins GRP78 and PDI. bFGF also decreased brain infarction volumes and conferred long-term neuroprotective effects against brain atrophy and neuron loss after HI brain injury.
|
28337259 |
2017 |
Harlequin Fetus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that the unfolded protein response (UPR) was strongly activated after HI injury and that bFGF significantly reduced the levels of the ER stress signalling proteins GRP78 and PDI. bFGF also decreased brain infarction volumes and conferred long-term neuroprotective effects against brain atrophy and neuron loss after HI brain injury.
|
28337259 |
2017 |
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results also raise the possibility that PAD1 may function as an important new biomarker for TNBC tumors and suggest that PAD1-specific inhibitors could potentially be utilized to treat metastatic breast cancer.
|
28844713 |
2017 |
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our data indicate that PAD1 appears to promote tumorigenesis by regulating MEK1-ERK1/2-MMP2 signaling in TNBC.
|
28844713 |
2017 |
Refractory cancer
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
For this purpose, conventional and pH-sensitive liposomes were formulated, compared regarding their physical-chemical properties (size, PDI, morphology, in vitro stability and drug release) and studied for in vitro cytotoxicity against a cDDP-resistant cancer cells.
|
27885848 |
2017 |